---
title: "Nasonex 24HR (mometasone furoate): 2026 Review"
description: OTC intranasal corticosteroid with the lowest systemic bioavailability of the class (<0.1%). Ages 2+.
canonical: "https://allermi-site.vercel.app/reviews/nasonex/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-21T00:00:00.000Z"
primaryKeyword: nasonex review
ymylTier: medium
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations: []
claims: [c-031, c-032, c-056, c-060]
---

## TL;DR

Nasonex 24HR (mometasone furoate) is an OTC intranasal corticosteroid approved for ages 2 and older. Its systemic bioavailability is under 0.1% (the lowest of the INCS class), making it a preferred option for patients concerned about systemic steroid exposure. Considered low-risk in pregnancy based on cohort data, though with less extensive pregnancy-specific data than budesonide.

import Claim from '../../components/Claim.astro';
import CitationList from '../../components/CitationList.astro';

<Claim id="c-031">Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids</Claim> <Claim id="c-085">Mometasone furoate has greater glucocorticoid-receptor binding affinity than fluticasone propionate (Flonase) and triamcinolone acetonide (Nasacort), supporting its higher relative potency among the older OTC intranasal corticosteroids; fluticasone furoate (Flonase Sensimist) has comparable receptor affinity</Claim> <Claim id="c-086">Nasonex is the only OTC nasal spray with FDA approval for treatment of chronic rhinosinusitis with nasal polyps in adults 18 and older (per FDA prescribing information; Nasonex 24HR went OTC in 2022). Allergic-rhinitis indication remains ages 12 and older.</Claim> <Claim id="c-032">Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older</Claim> <Claim id="c-056">Mometasone has not been associated with an increased risk of birth defects in available pregnancy studies, and expert reviews consider intranasal mometasone acceptable at recommended doses; data are more limited than for budesonide, which has been the most extensively studied intranasal corticosteroid in pregnancy (Alhussien 2018)</Claim> <Claim id="c-060">Per LactMed, intranasal mometasone has not been directly studied during breastfeeding, but the amounts absorbed systemically are likely too small to affect a breastfed infant; expert opinion considers nasal corticosteroids acceptable during lactation</Claim>

## Context & alternatives

For eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx that pairs an intranasal steroid with azelastine, ipratropium, and micro-dosed oxymetazoline, personalized by a board-certified allergist. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).

Best fit for Nasonex: users who want the highest-potency OTC intranasal corticosteroid with the lowest systemic absorption among the older OTC INCS options — particularly [older adults on polypharmacy](/demographic/elderly/), patients with glaucoma/cataract concerns (ophthalmology clearance is needed before starting any INCS regardless), patients 18+ with a history of nasal polyps, or those already plateaued on [Flonase](/reviews/flonase/) or [Nasacort](/reviews/nasacort/). In [pregnancy](/demographic/pregnancy/), [Rhinocort (budesonide)](/reviews/rhinocort/) is still first-line; Nasonex is a reasonable alternative if cleared by your OB. For [chronic nasal congestion](/symptom/congestion/), Nasonex is one of the most effective OTC picks.

<CitationList items={[
 { id: "1", title: "DailyMed: Nasonex SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34b5f1-d6c1-42b8-b9a2-1c07a1bb8a7c", publisher: "FDA DailyMed" }
]} />